RT Journal Article
SR Electronic
T1 Neurosarcoidosis
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e743
DO 10.1212/NXI.0000000000000743
VO 7
IS 4
A1 Lord, Jennifer
A1 Paz Soldan, M. Mateo
A1 Galli, Jonathan
A1 Salzman, Karen L.
A1 Kresser, Jacob
A1 Bacharach, Rae
A1 DeWitt, L. Dana
A1 Klein, Julia
A1 Rose, John
A1 Greenlee, John
A1 Clardy, Stacey L.
YR 2020
UL http://nn.neurology.org/content/7/4/e743.abstract
AB Objective To characterize patients with neurosarcoidosis within the University of Utah healthcare system, including demographics, clinical characteristics, treatment, and long-term outcomes.Methods We describe the clinical features and outcomes of patients with neurosarcoidosis within the University of Utah healthcare system (a large referral center for 10% of the continental United States by land mass). Patients were selected who met the following criteria: (1) at least one International Classification of Diseases Clinical Modification, 9th revision code 135 or International Classification of Diseases Clinical Modification, 10th revision code D86* (sarcoidosis) and (2) at least one outpatient visit with a University of Utah clinician in the Neurology Department within the University of Utah electronic health record.Results We identified 56 patients meeting the study criteria. Thirty-five patients (63%) were women, and most patients (84%) were white. Twelve patients (22%) met the criteria for definite neurosarcoidosis, 36 patients (64%) were diagnosed with probable neurosarcoidosis, and 8 patients (14%) were diagnosed with possible neurosarcoidosis. A total of 8 medications were used for the treatment of neurosarcoidosis. Prednisone was the first-line treatment in 51 patients (91%). Infliximab was the most effective therapy, with 87% of patients remaining stable or improving on infliximab. Treatment response for methotrexate and azathioprine was mixed, and mycophenolate mofetil and rituximab were the least effective treatments in this cohort.Conclusions This is a comprehensive characterization of neurosarcoidosis within a single healthcare system at the University of Utah that reports long-term response to treatment and outcomes of patients with neurosarcoidosis. Our results suggest the use of infliximab as a first-line therapy for neurosarcoidosis.ACE=angiotensin-converting enzyme; CVID=common variable immune deficiency; PNS=peripheral nervous system; TNFα=tumor necrosis factor-alpha